Siemens Medical Solutions (www.siemens.com/medical) expanded its molecular imaging research collaboration with The University of Texas M. D. Anderson Cancer Center with the establishment of a preclinical research center for the development of new, targeted biomarkers. The goal is to help detect cancers earlier, better visualize the disease at the molecular level, and provide more effective, tailored therapies.

The center will be located on the M. D. Anderson campus in Houston. Researchers from Siemens and M. D. Anderson will work together at the facility to develop novel radio-labeled imaging agents that visualize molecular genetic targets.

As part of the agreement, researchers at M. D. Anderson will perform preclinical testing of Siemens’ proprietary and licensed compounds as well as participate in Siemens’ clinical trials. Siemens will have certain rights to license imaging agents developed through the research.








This site uses Akismet to reduce spam. Learn how your comment data is processed.